Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FusionVAC22_02 in FL-HCC and other tumors
NCT06789198Phase 1Recruiting
- Sponsor
- University Hospital Tübingen
- Start
- Jul 2025
- Primary completion
- Nov 2028
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DNAJB1-PRKACA peptide vaccine in fibrolamellar hepatocellular carcinoma (FLHCC), sponsored by University Hospital Tübingen. Primary endpoints: Efficacy of vaccination and Safety of the vaccination. Started Jul 2025; status: recruiting.
02
Drugs
DNAJB1-PRKACA peptide vaccine
03
Conditions
fibrolamellar hepatocellular carcinoma (FLHCC)
Beyond the preview
Go deeper on NCT06789198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06789198.